It might act like a biopharmaceutical firm, but Wuxi Apptec remains a contract research organization, with aims of fostering innovation by offering an open access platform to the biopharma industry.
Richard M. Soll, Wuxi's senior vice president of the international discovery service unit, sat down with BioWorld at the recent BIO International Convention in San Diego to discuss the firm's evolving capabilities. He also offered insight into Wuxi's role in helping to obtain the first U.S. FDA approval for a biologic product developed by a Chinese company.
News & Views is BioWorld's new series of video interviews with key biopharma executives, in which those experts and thought leaders share the latest clinical updates, provide insights into recent deals and financings and tackle a variety of questions.
Click here for BioWorld's interview with Wuxi's Soll.